Docetaxel Prednisone Prostate Cancer

Listing Websites about Docetaxel Prednisone Prostate Cancer

Filter Type:

Docetaxel + Prednisone - Prostate Cancer ChemoExperts

(3 days ago) Docetaxel is designed to directly kill prostate cancer cells. Prednisone is designed to slow the growth of prostate cancer cells by decreasing testosterone production from the adrenal glands. Goals of therapy: Docetaxel + Prednisone has been shown to increase survival time and improve quality of life, but is not commonly given with the goal of

https://www.chemoexperts.com/docetaxel-taxotere-prednisone.html

Category:  Prostate cancer Show Health

The Influence of Prednisone on the Efficacy of Docetaxel

(3 days ago) Prednisone and other corticosteroids can provide palliation and tumor responses in patients with prostate cancer. The combination of docetaxel and prednisone was the first treatment shown to prolong survival in men with metastatic castration-resistant prostate cancer (mCRPC). Since …

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748735/

Category:  Prostate cancer Show Health

Docetaxel plus Prednisone or Mitoxantrone plus …

(Just Now) In this phase 3 study, two schedules of docetaxel administered with prednisone were compared with mitoxantrone plus prednisone, the standard chemotherapy for hormone-refractory prostate cancer.

https://www.nejm.org/doi/full/10.1056/NEJMoa040720

Category:  Prostate cancer Show Health

Docetaxel and Prednisolone for prostate cancer

(2 days ago) for prostate cancer Docetaxel-Prednisolone CRP-09 U002 -v2.3 Page 1 of 3 Issue Date 16/03/2018 Expiry Date 08/03/2021 DRUG ADMINISTRATION SCHEDULE1 Day Drug Dose Route Diluent & Rate Day 0 to day 2 Dexamethasone 8mg BD* Oral For 3 days Day 1 …

https://www.northerncanceralliance.nhs.uk/wp-content/uploads/2018/11/Docetaxel-Prednisolone-CRP-09-U002-v2.3.pdf

Category:  Prostate cancer Show Health

Docetaxel plus prednisone or mitoxantrone plus …

(1 days ago) Purpose: The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen …

https://pubmed.ncbi.nlm.nih.gov/18182665/

Category:  Prostate cancer Show Health

Docetaxel plus prednisone or mitoxantrone plus …

(1 days ago) Background: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. Methods: From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of …

https://pubmed.ncbi.nlm.nih.gov/15470213/

Category:  Prostate cancer Show Health

Docetaxel Use in High-Risk Prostate Cancer: New Long …

(7 days ago) For the patients receiving docetaxel, the protocol called for 6 cycles of docetaxel 75 mg/m 2 intravenously (IV) over 1 hour every 21 days and …

https://www.cancertherapyadvisor.com/home/cancer-topics/prostate-cancer/prostate-cancer-docetaxel-use-long-term-data-treatment/

Category:  Cancer Show Health

Chemotherapy Protocol PROSTATE DOCETAXEL(75) …

(6 days ago) Prostate-Docetaxel(75)-Prednisolone As take home medication - metoclopramide 10mg oral three times a day for 3 days then as required Coding (OPCS) Procurement – X71.1 Delivery – X72.3 References 1.Tannock IF, deWit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

https://www.uhs.nhs.uk/Media/SUHTExtranet/Services/Chemotherapy-SOPs/Prostatecancer/Docetaxel%20(75)-Prednisolone%20ver1.2.pdf

Category:  Prostate cancer Show Health

Prostate Cancer Treatment Regimens - Cancer Therapy …

(2 days ago) 25. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J …

https://www.cancertherapyadvisor.com/home/cancer-topics/genitourinary-cancer/genitourinary-cancer-treatment-regimens/prostate-cancer-treatment-regimens/

Category:  Prostate cancer Show Health

BC Cancer Protocol Summary for Palliative Therapy …

(7 days ago) 2. Petrylak DP, Macarthur RB, O’Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17:958-67. 3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12.

http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents/Genitourinary/GUPDOC_Protocol.pdf

Category:  Prostate cancer Show Health

Chemotherapy Protocol PROSTATE DOCETAXEL(75) …

(7 days ago) Prostate-Docetaxel (75)-Prednisolone (6 cycles) Indication First line treatment of prostate cancer in combination with androgen deprivation therapy for the treatment of hormone naive metastatic prostate cancer (this is an unlicensed indication). Performance status 0, 1, 2

https://www.uhs.nhs.uk/Media/SUHTExtranet/Services/Chemotherapy-SOPs/Prostatecancer/Docetaxel-75-Prednisolone-6-cycles-Ver1.pdf

Category:  Prostate cancer Show Health

Multiple Docetaxel Retreatments Without Prednisone for

(3 days ago) Introduction. Since 2004 the standard first-line treatment option for metastatic castration-resistant prostate cancer (mCRPC) has been 3 weekly series of docetaxel (DOC) plus prednisone providing a survival benefit of 2–3 months compared to mitoxantrone plus prednisone [].The current DOC treatment is administered in a single series of 6–10 treatment cycles, as patients with CPRC …

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280015/

Category:  Prostate cancer Show Health

Current treatment options for newly diagnosed metastatic

(3 days ago) In a multi-arm, multi-stage design, the STAMPEDE group recruited 2,962 men with hormone-sensitive prostate cancer to be randomised to receive ADT, ADT plus Docetaxel (75 mg/m 2 intravenously every 3 weeks for six weeks) plus prednisolone, ADT plus zoledronic acid or ADT plus Docetaxel plus zoledronic acid. Median age of men in all arms were

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575582/

Category:  Prostate cancer Show Health

Cabozantinib plus docetaxel and prednisone in metastatic

(1 days ago) Objective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel. Patients and methods: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m 2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg).

https://pubmed.ncbi.nlm.nih.gov/32969563/

Category:  Prostate cancer Show Health

Docetaxel/Prednisone Plus Fractionated 177Lu- J591

(7 days ago) Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it …

https://clinicaltrials.gov/ct2/show/NCT00916123

Category:  Prostate cancer Show Health

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone

(7 days ago) n engl j med 351;15 www.nejm.org october 7, 2004 docetaxel versus mitoxantrone for prostate cancer 1503 rostate cancer is the most com-mon cancer among men, with approximate-

https://www.nejm.org/doi/pdf/10.1056/NEJMoa040720?articleTools=true

Category:  Prostate cancer Show Health

The New Combination Docetaxel, Prednisone and Curcumin in

(1 days ago) Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). Methods: Thirty patients with progressing CRPC and a rising prostate-specific antigen (PSA) received docetaxel/prednisone in standard conditions for 6 cycles in combination with per os

https://pubmed.ncbi.nlm.nih.gov/26771576/

Category:  Prostate cancer Show Health

Circulating Tumor Cells in a Phase 3 Study of Docetaxel

(1 days ago) The association between CTC counts (at baseline or after treatment), overall survival (OS), and response to docetaxel with lenalidomide was evaluated in a 208-patient subset from the MAINSAIL trial, which compared docetaxel-prednisone-lenalidomide and docetaxel-prednisone-placebo in metastatic castration-resistant prostate cancer patients.

https://pubmed.ncbi.nlm.nih.gov/27522164/

Category:  Prostate cancer Show Health

Practical Guidance on the Role of Corticosteroids in the

(7 days ago) Results from the STAMPEDE study, in which some patients with castration-sensitive prostate cancer received treatment with ADT and docetaxel plus prednisone 10 mg daily, showed a 10-month increase in median survival compared with ADT alone. 2 This significant increase in survival was similar to the 13.5-month increase in median survival observed

https://www.sciencedirect.com/science/article/pii/S0090429516001461

Category:  Prostate cancer Show Health

Docetaxel Dosage Guide + Max Dose, Adjustments - Drugs.com

(3 days ago) -For hormone-refractory metastatic prostate cancer, because of the concurrent use of prednisone, the recommended premedication regimen is dexamethasone 8 mg orally, at 12 hours, 3 hours, and 1 hour before docetaxel. Use: In combination with prednisone for androgen independent (hormone refractory) metastatic prostate cancer. Renal Dose Adjustments

https://www.drugs.com/dosage/docetaxel.html

Category:  Prostate cancer Show Health

Comparative Effectiveness of Mitoxantrone Plus Prednisone

(3 days ago) Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure Angela K. Green , a, * Robert W. Corty , b, * William A. Wood , a Mathew Meeneghan , a Katherine E. Reeder-Hayes , a Ethan Basch , a Matthew I. Milowsky , a and Stacie B. Dusetzina c, d

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425389/

Category:  Prostate cancer Show Health

Docetaxel to Treat Prostate Cancer Benefits and Risks

(6 days ago) Docetaxel is currently approved in the US for the treatment of head and neck cancer, gastric cancer, breast cancer, prostate cancer, and non-small cell lung cancer, and it is commercialized under the brand name Taxotere, by the pharmaceutical company Aventis Pharmaceuticals, Inc.

https://prostatecancernewstoday.com/docetaxel/

Category:  Prostate cancer Show Health

Docetaxel + Prednisone With or Without Radiation for

(7 days ago) Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

https://clinicaltrials.gov/ct2/show/NCT01087580

Category:  Prostate cancer Show Health

Current treatment strategies for advanced prostate cancer

(3 days ago) mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–12. 4 de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–54.

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/iju.13512

Category:  Prostate cancer Show Health

Ribociclib, Docetaxel, and Prednisone in Treating Patients

(8 days ago) Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving ribociclib together with docetaxel and carboplatin may work better in treating metastatic castration-resistant prostate cancer.

https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2015-01797

Category:  Prostate cancer Show Health

Docetaxel and Estramustine Compared with Mitoxantrone and

(5 days ago) Original Article Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer I.F. Tannock and Others Perspective From Culture to Vaccine — Salk and Sabin S.L. Katz

https://www.nejm.org/doi/10.1056/NEJMoa041318

Category:  Prostate cancer Show Health

Survival Rates of Prostate Cancer Chemotherapy Treatment

(5 days ago)Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer” Mario Eisenberger M.D. (R. Dale Hughes Professor of Oncology at Johns Hopkins Kimmel Cancer Center) Dr. Ian Tannock of Princess Margaret Hospital (senior scientist with Ontario Cancer Institute and professor with the University of Toronto), et al.

https://www.prostate-cancer.com/chemotherapy/survival-rates/prostate-chemotherapy-survival.html

Category:  Prostate cancer Show Health

Phase 1/2 study of orteronel (TAK-700), an investigational

(3 days ago) Docetaxelprednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated orteronel plus DP in mCRPC patients.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390470/

Category:  Prostate cancer Show Health

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to

(7 days ago) Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

https://clinicaltrials.gov/ct2/show/NCT00089609

Category:  Prostate cancer Show Health

Prednisone Added to ADT Plus Docetaxel Improves

(9 days ago) “At least, men with de novo high volume metastatic prostate cancer should be offered ADT plus docetaxel plus abiraterone based on evidence that this treatment combination will …

https://www.onclive.com/view/prednisone-added-to-adt-plus-docetaxel-improves-radiographic-pfs-and-os-in-mcspc

Category:  Prostate cancer Show Health

Masitinib Plus Docetaxel in Metastatic Castration

(7 days ago) The objective of this study is to evaluate the efficacy and safety of masitinib in combination with docetaxel and prednisone with respect to placebo in combination with docetaxel and prednisone in the treatment of first line metastatic Castrate Resistant Prostate Cancer (mCRPC).

https://clinicaltrials.gov/ct2/show/NCT03761225

Category:  Prostate cancer Show Health

Abiraterone acetate plus prednisone versus placebo plus

(7 days ago) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet , 376 ( 2010 ) …

https://www.sciencedirect.com/science/article/pii/S1470204514712057

Category:  Prostate cancer Show Health

Effects of prednisone on docetaxel pharmacokinetics in men

(1 days ago) Aims. Docetaxel has been approved for the treatment of metastatic prostate cancer in combination with prednisone. Since prednisone is known to induce the cytochrome P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the liver, a potential drug–drug interaction may occur.

https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.13889

Category:  Prostate cancer Show Health

ZYTIGA Castration-Sensitive Prostate Cancer SUMMARY

(2 days ago) • Men with metastatic hormone-sensitive prostate cancer (mHSPC) who received either ADT alone, ZYTIGA plus prednisone with ADT, or docetaxel with ADT were prospectively followed for treatment outcomes. Seventy-six patients with ≥6 months follow-up were included in the analyses. ZYTIGA plus prednisone with ADT achieved a higher

https://www.janssenmd.com/zytiga/clinical-use/comparative-use/zytiga-comparison-of-zytiga-to-docetaxel-in-metastatic-castrationsensitive-prostate-cancer

Category:  Prostate cancer Show Health

Efficacy and safety of abiraterone acetate plus prednisone

(3 days ago) Background. Since the landmark study by Huggins et al. [] in 1941, once a patient with prostate cancer progresses after local therapy, either medical or surgical androgen-deprivation therapy constitutes the mainstay of treatment for metastatic disease [].In patients with metastatic castration-resistant prostate cancer (mCRPC), docetaxel in combination with prednisone was the first regimen to

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683519/

Category:  Prostate cancer Show Health

Abiraterone Plus ADT and Docetaxel: A New SOC for

(4 days ago) “Adding abiraterone and prednisone to ADT plus docetaxel clearly improves radiographic PFS in men with de novo metastatic prostate cancer,” Dr Fizazi said in closing.

https://www.cancertherapyadvisor.com/home/news/conference-coverage/asco-2021/prostate-cancer-abiraterone-adt-docetaxel-treatment-risk/

Category:  Prostate cancer Show Health

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone

(9 days ago) Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate

https://ascopubs.org/doi/10.1200/JCO.2007.12.4008

Category:  Prostate cancer Show Health

Docetaxel in Combination With GVAX ® Immunotherapy Versus

(7 days ago) Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

https://clinicaltrials.gov/ct2/show/NCT00133224

Category:  Prostate cancer Show Health

Metastatic Castrate-Resistant Prostate Cancer Treatment

(3 days ago) TROPIC (Cabazitaxel) 2010 Post-docetaxel CRPC Mitoxantrone Prednisone 0.70 <0.0001 COU-AA-301 (Abiraterone acetate) 2010 Post-docetaxel CRPC Placebo Prednisone 0.65 <0.0001 ALSYPMCA (Radium 223) 2013 Post-docetaxel CRPC BSC 0.71 <0.00046 AFFIRM (Enzalutamide) 2012 Post-docetaxel CRPC BSC 0.63 <0.0001

https://oncologypro.esmo.org/content/download/127838/2410993/1/E-Learning-Metastatic-Castrate-Resistant-Prostate-Cancer-Treatment.pdf

Category:  Cancer Show Health

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone

(3 days ago) The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had

https://ascopubs.org/doi/pdf/10.1200/jco.2007.12.4008

Category:  Prostate cancer Show Health

Cabozantinib plus docetaxel and prednisone in metastatic

(7 days ago) This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m 2 every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg). Based on the results of the phase 1 study, the investigation was expanded into a randomized

https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15227

Category:  Prostate cancer Show Health

Taxotere + Prednisone Chemotherapy, Side Effects

(5 days ago) How Taxotere + Prednisone chemotherapy is given and possible side effects. Taxotere + Prednisone for the treatment of Prostate Cancer. Taxotere (docetaxel) + Prednisone is a treatment regimen for prostate cancer.

https://www.navigatingcare.com/chemotherapy_treatments/docetaxel-prednisone

Category:  Prostate cancer Show Health

Chemotherapy for androgen-independent prostate cancer Meta

(1 days ago) While men with metastatic prostate cancer frequently show a good initial response to androgen ablation, few options have been available for progressive hormone-refractory prostate cancer, and survival following chemotherapy has not exceeded 9 to 12 months. The combination of prednisone and mitoxantrone has significant palliative effects on bone pain but does not extend survival. The

https://khepri-node.dev.meta-infra.org/papers/chemotherapy-for-androgen-independent-prostate/12198636

Category:  Prostate cancer Show Health

Docetaxel and epirubicin compared with docetaxel and

(Just Now) Petrioli, R., Pascucci, A., Conca, R. et al. Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: …

https://www.nature.com/articles/bjc20115

Category:  Prostate cancer Show Health

Custirsen in combination with docetaxel and prednisone for

(7 days ago) Since 2004, the standard first-line chemotherapy for treatment of metastatic castration-resistant prostate cancer has been docetaxel with prednisone. 2 Over the past 5 years, several new treatment options have been introduced that improve overall survival, including the androgen receptor axis-targeting agents abiraterone3, 4 and enzalutamide5

https://www.sciencedirect.com/science/article/pii/S1470204517301687

Category:  Prostate cancer Show Health

Molecular mechanisms of docetaxel resistance in prostate

(Just Now) Docetaxel (DTX) chemotherapy offers excellent initial response and confers significant survival benefit in patients with castration-resistant prostate cancer (CRPC). However, the clinical utility of DTX is compromised when primary and acquired resistance are encountered. Therefore, a more thorough understanding of DTX resistance mechanisms may

https://cdrjournal.com/article/view/3613

Category:  Prostate cancer Show Health

Filter Type: